Camillo Porta

University of Pavia

Papers

3

Total Citations

3,048

H-Index

3

About

Camillo Porta is a leading authority in the clinical management of renal cell carcinoma (RCC), with a career dedicated to advancing treatment paradigms for this challenging malignancy. His most impactful contributions come through his central role in authoring the ESMO Clinical Practice Guidelines for RCC, which have collectively garnered over 3,000 citations. These landmark documents, published in 2012, 2014, and 2016, have served as the global gold standard for diagnosis, treatment, and follow-up, shaping clinical decision-making and harmonizing care across institutions. Porta’s work integrates evidence-based medicine with practical clinical insights, bridging the gap between cutting-edge research and bedside application. Beyond guideline authorship, his research has explored prognostic factors, targeted therapies, and immunotherapies, influencing how clinicians approach patient stratification and sequencing of treatments. His sustained impact is reflected not only in citation counts but in the widespread adoption of his recommendations, making him a pivotal figure in the evolution of RCC management and a trusted voice for oncologists worldwide.

Research Focus

Key Achievements

3
H-Index
3
Papers
3,048
Total Citations
1,016
Avg Citations/Paper
🏆 Most Cited Paper
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2,259 citations · 2014
📈 Most Prolific Year: 2014 (1 Papers)
🤝 Key Collaborators: 13
🏛 Institutions: University of Pavia

Top Papers

  1. 1
  2. 2
  3. 3

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago